Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Navarixin

Generic Name: Navarixin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅N_₃O_₅

CAS Number: 473727-83-2

Unique Ingredient Identifier: 4GMU5HUX5I

Overview

Navarixin has been investigated for the treatment of Asthma.

Background

Navarixin has been investigated for the treatment of Asthma.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Phase 2

Completed

Posted: 2018/03/22

Sponsor:Merck Sharp & Dohme ...

ID:NCT03473925

Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)

Phase 1

Terminated

Posted: 2010/02/12

Sponsor:Merck Sharp & Dohme ...

ID:NCT01068145

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

Phase 2

Terminated

Posted: 2009/11/03

Sponsor:Merck Sharp & Dohme ...

ID:NCT01006616

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Phase 2

Withdrawn

Posted: 2009/11/01

Sponsor:Merck Sharp & Dohme ...

ID:NCT01006161

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Phase 2

Completed

Posted: 2008/06/03

Sponsor:Merck Sharp & Dohme ...

ID:NCT00688467

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy